ArticleJournal for immunotherapy of cancer2021

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.

Gabrielle Leclercq et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.